Beer Ambros J, Schwaiger Markus
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich 81675, Germany.
Methods Mol Biol. 2011;680:183-200. doi: 10.1007/978-1-60761-901-7_13.
Imaging of αvβ3 expression in malignant diseases has been extensively studied in the last years, mainly because the level of integrin αvβ3 expression might be a surrogate parameter of angiogenic activity. Most studies have been performed using preclinical tumor models but recently first results if imaging αvβ3 expression in patients have been published. The first approach used was the radiotracer approach with tracers for positron emission tomography (PET) like [(18)F]Galacto-RGD or tracers for single photon emission computed tomography (SPECT) like [(99m)Tc]NC100692. In this article we will focus on the experimental design and methodology of PET imaging of αvβ3 expression with the tracer [(18)F]Galacto-RGD. Common difficulties and pitfalls in image acquisition and interpretation will be discussed. Finally, the performance of PET will be compared to other methods of imaging of αvβ3 expression, like magnetic resonance imaging, ultrasound, or optical imaging.
近年来，恶性疾病中αvβ3表达的成像研究广泛开展，主要是因为整合素αvβ3的表达水平可能是血管生成活性的替代参数。大多数研究使用临床前肿瘤模型进行，但最近已发表了在患者中对αvβ3表达进行成像的初步结果。最初采用的方法是放射性示踪剂法，用于正电子发射断层扫描（PET）的示踪剂如[(18)F]半乳糖-RGD，或用于单光子发射计算机断层扫描（SPECT）的示踪剂如[(99m)Tc]NC100692。在本文中，我们将重点关注使用示踪剂[(18)F]半乳糖-RGD对αvβ3表达进行PET成像的实验设计和方法。还将讨论图像采集和解读中的常见困难与陷阱。最后，将PET的性能与αvβ3表达成像的其他方法进行比较，如磁共振成像、超声或光学成像。
